about
Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapiesInduced protein degradation: an emerging drug discovery paradigm.Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential.SCF ubiquitin ligase-targeted therapies.Epic $12 billion deal and FDA's approval raise CAR-T to new heights.Nature Biotechnology's academic spinouts of 2014.Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
P2860
Q28085769-9DA4C940-E9CC-4040-A90D-393E08787C04Q34545841-D9B5B885-80C2-4717-8DB2-D1603ABFEE6BQ37523030-FF944048-631D-4348-B95D-6EDCDE588307Q38267996-C9613881-545D-40DA-9855-07F0AE90586DQ50027026-01839650-D27B-4A53-8D7C-08218A374367Q52423443-DC876917-4190-4E01-BB2D-F8245AC27294Q58738119-D8A21785-E2B8-4AA2-A918-96AAA1B2774E
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Nature Biotechnology's academic spinouts of 2013.
@ast
Nature Biotechnology's academic spinouts of 2013.
@en
type
label
Nature Biotechnology's academic spinouts of 2013.
@ast
Nature Biotechnology's academic spinouts of 2013.
@en
prefLabel
Nature Biotechnology's academic spinouts of 2013.
@ast
Nature Biotechnology's academic spinouts of 2013.
@en
P2093
P2860
P356
P1433
P1476
Nature Biotechnology's academic spinouts of 2013.
@en
P2093
Aaron Bouchie
Laura DeFrancesco
Malorye Allison
Sarah Webb
P2860
P2888
P304
P356
10.1038/NBT.2846
P577
2014-03-01T00:00:00Z